Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT02531152 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02531152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02531152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
April 30, 2016
Enrollment
54 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

open angle glaucoma -ocular hypertension